NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ImmunoGen, Inc. 

128 Sidney Street

Cambridge  Massachusetts  02139-4239  U.S.A.
Phone: 617-995-2500 Fax: 617-995-2510


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

GlaxoSmithKline (North Carolina) 

Raven Biotechnologies, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.

Medarex, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.





 Company News
ImmunoGen, Inc. (IMGN) Licenses Anti-Cancer Technology to Amgen (AMGN) (JOBS); ImmunoGen to Get Up to $34 Million in Milestone Payments 11/20/2009 6:39:39 AM    More...
ImmunoGen, Inc. (IMGN) Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma 11/17/2009 11:16:02 AM    More...
ImmunoGen, Inc. (IMGN) Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders 11/11/2009 1:40:19 PM    More...
ImmunoGen, Inc. (IMGN) Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 11/10/2009 9:41:13 AM    More...
ImmunoGen, Inc. (IMGN) Reports First Quarter Fiscal Year 2010 Financial Results 10/30/2009 9:18:33 AM    More...
ImmunoGen, Inc. (IMGN) Announces Conference Call to Discuss its First Quarter Fiscal Year 2010 Financial Results 10/22/2009 9:45:08 AM    More...
ImmunoGen, Inc. (IMGN) Licenses Anticancer Technology to Amgen (AMGN) (JOBS); Deal Worth up to $35 Million 9/17/2009 7:40:26 AM    More...
ImmunoGen, Inc. (IMGN) President and CEO to Ring The NASDAQ Stock Market Closing Bell 9/15/2009 8:58:39 AM    More...
ImmunoGen, Inc. (IMGN) Announces Webcast of Presentations at Two Investor Conferences 9/2/2009 8:56:41 AM    More...
ImmunoGen, Inc. (IMGN) Appoints Peter Williams as Vice President, Business Development 8/17/2009 9:06:47 AM    More...
12345678910...